Recommend Human Vaccines to your librarian for 2008. Download form here.

Sign up for TOC Alerts

Email this page

Print this page

Commentary

Group B streptococcal conjugate vaccine: A timely concept for which the time has come

Morven S. Edwards

Purchase article for $19

Subscribe to this journal for $79/year

Invasive disease due to group B Streptococcus (GBS) has been recognized as a threat to the health of pregnant women and their infants for almost half a century. Development of GBS vaccine candidates has progressed at an exemplary pace given lack of manufacturer development, but efficacy testing of candidate GBS conjugate vaccines has been mired in economic and regulatory concerns for longer than a decade. A trivalent or pentavalent vaccine will be required, and decisions must be made as to the criteria by which efficacy will be determined and the population in whom efficacy will be assessed. Concerns regarding durability of conjugate vaccine-derived immunity, pregnant women as a possible target group and regulatory issues required for licensing must be resolved if the prospect of impacting GBS disease burden through immunization is to become a reality.

Authors

Morven S. Edwards

Section of Infectious Diseases; Departments of Pediatrics; Baylor College of Medicine, Houston, Texas USA

Purchase article for $19

Subscribe to this journal for $79/year